Cold, Flu & Cough News and Research

Latest Cold, Flu & Cough News and Research

Sinovac Biotech's sales for first-quarter 2010 decrease 32% to $4.4M

Sinovac Biotech Ltd., a leading China-based vaccine manufacturer, announced today its unaudited financial results for the three-month period ended March 31, 2010.

14 May 2010

Nephros reports 57% increase in revenues for first-quarter 2010

Nephros, Inc. announced today financial results for the three months ended March 31, 2010.

14 May 2010

Chimerix commences first-in-human study of CMX157 for HIV

Chimerix, Inc., a biotechnology company developing orally-available antiviral therapeutics, announced the commencement of a first-in-human study of CMX157, a novel lipid conjugate of the nucleotide tenofovir with in vitro activity against both tenofovir-sensitive and tenofovir-resistant human immunodeficiency virus (HIV). CMX157 has the potential to increase efficacy and decrease toxicity as compared to tenofovir, and may enable the creation of new 'one pill, once-a-day', fixed-dose combination regimens for the treatment of HIV infection.

14 May 2010

U.S. Well-Being Report for April 2010

The Gallup-Healthways Well-Being Index was a tie (63.3) for all-time overall well-being in April, revealing a continued recovery of American well-being despite continuing challenges and high unemployment. The only other time in 28 months of measurement the WBI reached 67 was in August 2009.

13 May 2010

AlphaRx continues to develop Indaflex for the Chinese market

AlphaRx, Inc., has been advised by Cypress Biosciences, its development partner for Indaflex, that Cypress is not funding development of Indaflex. Notwithstanding to the termination of all Indaflex activity in the U.S.A., AlphaRx continues to develop Indaflex for the Chinese market.

13 May 2010

Advances in vaccine delivery and efficacy discussed at National Immunization Conference

Advances in vaccine delivery and efficacy were discussed at the 44th National Immunization Conference sponsored by the Centers for Disease Control and Prevention. A research study by each of the four directors from the Center for Vaccine Awareness and Research at Texas Children's Hospital was presented.

13 May 2010

Sex can affect frequency and severity of adverse effects of vaccination

Biological differences between the sexes could be a significant predictor of responses to vaccines, according to researchers at the Johns Hopkins Bloomberg School of Public Health. They examined published data from numerous adult and child vaccine trials and found that sex is a fundamental, but often overlooked predictor of vaccine response that could help predict the efficacy of combating infectious disease.

13 May 2010

Two-thirds of child deaths in 2008 due to infectious diseases, report finds

Pneumonia, diarrhea, malaria and other infectious diseases accounted for two-thirds of the 8.8 million deaths in 2008 among children under age 5 around the world, according to a Lancet study published on Wednesday, HealthDay News/Bloomberg BusinessWeek reports. The highest numbers of childhood deaths were in Africa (4.2 million) and Southeast Asia (2.39 million), according to the news service (5/11).

13 May 2010

FDA approves Sagent's bacitracin for pneumonia and empyema

Sagent Pharmaceuticals, Inc., a privately held specialty pharmaceutical company, today announced FDA approval of bacitracin for injection, USP (bacitracin), an anti-infective product used to treat pneumonia and empyema. Bacitracin will be offered in a 50,000 MU, AP-rated, preservative-free, latex-free, single-dose vial packaged both individually and in packages of ten.

13 May 2010

Seaside purchases NanoViricides' Series B Convertible Preferred Stock for gross proceeds of $5M

NanoViricides, Inc., announced today that it has raised $5,000,000, drawing down on its previously announced universal registered shelf "Form S-3" offering. The registered shelf offering became effective on April 29, 2010.

12 May 2010

MRSA Survivors Network to raise awareness on MRSA infections

More Americans die annually from invasive methicillin-resistant Staphylococcus aureus infections than from HIV/AIDS, H1N1 influenza and Parkinson's disease, yet the United States and many other countries' health officials continue to ignore the global crisis.

12 May 2010

MicroStockProfit.com releases investment report featuring Hemispherx Biopharma

MicroStockProfit.com announces an investment report featuring biopharmaceutical company Hemispherx Biopharma Inc. The report includes financial, comparative and investment analysis, and industry information you need to know to make an educated investment decision.

12 May 2010

Preventable infectious diseases cause two-thirds of child deaths: The Lancet

Preventable infectious diseases cause two-thirds of child deaths, according to a new study published today by The Lancet. Experts from the World Health Organization and UNICEF's Child Health Epidemiology Reference Group assessed data from 193 countries to produce estimates by country, region and the world.

12 May 2010

Gap between Hispanic and white asthma sufferers widen in the use daily medications

The gap between the proportion of black and white Americans with asthma who took an inhaled or oral medicine daily to prevent attacks grew wider between 2003 and 2006, according to the latest News and Numbers from the Agency for Healthcare Research and Quality.

12 May 2010

Vetter signs preferred partnership agreement with Sentry BioPharma Services

Vetter, a leading provider of aseptic pre-filled drug-delivery systems, and Sentry BioPharma Services, a provider of supply chain management and clinical packaging services, today announced that they have signed a preferred partnership agreement.

12 May 2010

FDA approves delivery of Cefepime in B. Braun's DUPLEX System

The U.S. Food and Drug Administration recently approved an application that permits B. Braun Medical Inc. (B. Braun) to deliver FDA-approved 1g and 2g Cefepime for Injection USP and Dextrose Injection USP in B. Braun's DUPLEX® Drug Delivery System.

From B. Braun Melsungen AG 12 May 2010

First Edition: May 11, 2010

Today's coverage includes more details regarding how the new health law moves forward with efforts to provide health insurance coverage to young adults.

11 May 2010

Hothead Technologies, Shafer partner to develop normothermia monitoring and management system

Hothead Technologies has executed an agreement with Shafer Medical Devices, a Division of Shafer Enterprises, LLC to develop and distribute a medical application of the H.O.T.™ System that supports the Shafer Medical Devices Hypo/Hyperthermic Pad in managing normothermia in patients, during pre-op, surgery, and post op.

11 May 2010

New multicenter trial achieves 71% survival in AML children

More individualized therapy and better supportive care helped push the survival for children with acute myeloid leukemia (AML) to 71 percent three years after diagnosis, according to new research led by St. Jude Children's Research Hospital investigators and reported in the medical journal The Lancet Oncology. The survival rate of 71 percent is 20 percent better than previously reported U.S. rates and is similar to the success achieved in a 2009 Japanese study, said Jeffrey Rubnitz, M.D., Ph.D., a member of the St. Jude Oncology department.

11 May 2010